News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Yazji Salim
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/04/2023 |
4
| Yazji Salim (Chief Medical Officer) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Disposed/sold 354,400 options
@ $5.3, valued at
$1.9M
Disposed/sold 92,075 options
@ $1.94, valued at
$178.6k
Disposed/sold 55,000 options
@ $1.04, valued at
$57.2k
Disposed/sold 210,000 options
@ $0.96, valued at
$201.6k
Granted 354,400 options
@ $0
Granted 92,075 options
@ $0
Granted 55,000 options
@ $0
Granted 210,000 options
@ $0
Granted 70,600 options
@ $0.31, valued at
$21.9k
|
|
| 07/05/2023 |
4
| Yazji Salim (Chief Medical Officer) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 16,299 shares
@ $0.36, valued at
$5.9k
|
|
| 04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/23/2023 |
4
| Yazji Salim (Chief Medical Officer) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Granted 210,000 options
@ $0.96, valued at
$201.6k
|
|
| 01/05/2023 |
4
| Yazji Salim (Chief Medical Officer) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 9,961 shares
@ $1.02, valued at
$10.2k
|
|
| 08/01/2022 |
4
| Yazji Salim (Chief Medical Officer) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Granted 82,500 shares
@ $0
Granted 55,000 options
@ $1.04, valued at
$57.2k
|
|
| 01/31/2022 |
4
| Yazji Salim (Chief Medical Officer) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Bought 10,000 shares
@ $1.69, valued at
$16.9k
|
|
| 01/24/2022 |
4
| Yazji Salim (Chief Medical Officer) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Granted 92,075 options
@ $1.94, valued at
$178.6k
|
|
| 01/05/2022 |
4
| Yazji Salim (Chief Medical Officer) has filed a Form 4 on Oncternal Therapeutics, Inc.|
Txns:
| Granted 57,137 shares
@ $0 |
|
| 05/27/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
|
|